Corpus ID: 152507033

Understanding and Incentivizing Biosimilars

@article{Kanter2012UnderstandingAI,
  title={Understanding and Incentivizing Biosimilars},
  author={Jason Kanter and Robin C Feldman},
  journal={Hastings Law Journal},
  year={2012},
  volume={64},
  pages={57}
}
Congress recently passed the Biosimilars Act in an attempt to replicate the success that generic small molecule drugs have enjoyed under the Hatch-Waxman Act. The Biosimilars Act provides a pathway for biosimilars to achieve quicker and less expensive FDA approval than what is required for a new biopharmaceutical. There is, however, greater uncertainty and cost associated with achieving the coveted biosimilarity status. This reflects the complex production methods of biopharmaceuticals, along… Expand

Figures from this paper

An overview of biosimilars
TLDR
This review attempt to highlight the differences between biosimilars and chemical generics, development stages, issues of concern with the use of biosimilar and need of appropriate regulations for their approval. Expand
Biosimilar safety considerations in clinical practice.
TLDR
Context is provided regarding key safety issues addressed in biosimilar development, approval, and delivery to inform oncologists on matters of safety to consider when prescribing biosimilars andinent issues about safety from countries or regions where biosimilARS are currently in use are reviewed. Expand
Biosimilars in oncology: from development to clinical practice.
TLDR
Education of physicians and other healthcare providers, payers, and patients about biosimilars may facilitate informed decision making, promote acceptance of biosimilar into clinical practice, increase accessibility, and expedite associated health and economic benefits. Expand
Biologics and biosimilars
TLDR
Biosimilars will provide clinical trial data demonstrating similar clinical effects, though there will always be some degree of uncertainty in how much clinical impact will be result from the variation in both innovate and biosimilar products. Expand
Developing oncology biosimilars: an essential approach for the future.
TLDR
Improved patient access to cancer therapies such as biologics and reducing healthcare costs are key initiatives of the US Government; the integration of approved biosimilars into clinical practice will be instrumental in accomplishing these goals. Expand
Biosimilar safety factors in clinical practice.
TLDR
Safety considerations in the development of biosimilars are an important focus of regulatory guidelines, although topics such as interchangeability, automatic substitution, and nomenclature are still being debated. Expand
Biosimilars: Rationale and current regulatory landscape.
  • E. Olech
  • Medicine
  • Seminars in arthritis and rheumatism
  • 2016
TLDR
The addition of biosimilars to the market has the potential to improve access to biologic therapies and following the pathways will help protect and maintain the integrity, quality, and safety of the biosimilar product. Expand
Key considerations in the preclinical development of biosimilars.
TLDR
The aim of this article is to increase understanding of the preclinical development and evaluation process for biosimilar, as required by the regulatory agencies, that precedes the clinical testing of biosimilars in humans. Expand
An overview of biosimilars
Biologics have become an increasingly important but also expensive part of the global medicinal cabinet. Generics of this class of drug, termed biosimilars, can relieve the financial burden onExpand
Drug Wars: How Big Pharma Raises Prices and Keeps Generics off the Market
While the shockingly high prices of prescription drugs continue to dominate the news, the strategies used by pharmaceutical companies to prevent generic competition are poorly understood, even by theExpand
...
1
2
...